1. Home
  2. DFLI vs CING Comparison

DFLI vs CING Comparison

Compare DFLI & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$1.09

Market Cap

18.8M

Sector

Technology

ML Signal

HOLD

CING

Cingulate Inc.

N/A

Current Price

$5.32

Market Cap

64.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DFLI
CING
Founded
2020
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8M
64.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DFLI
CING
Price
$1.09
$5.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.25
$34.50
AVG Volume (30 Days)
353.0K
146.1K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.47
EPS
N/A
N/A
Revenue
$58,630,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.77
N/A
52 Week Low
$0.26
$3.16
52 Week High
$5.15
$11.89

Technical Indicators

Market Signals
Indicator
DFLI
CING
Relative Strength Index (RSI) 37.19 55.62
Support Level $1.10 $4.76
Resistance Level $1.46 $5.54
Average True Range (ATR) 0.06 0.31
MACD 0.01 0.02
Stochastic Oscillator 17.39 56.06

Price Performance

Historical Comparison
DFLI
CING

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: